stars 1 stars 2 stars 3

Commit Biologics is creating a new drug category in immunotherapy by harnessing one of the immune system’s most ancient and powerful effector functions: complement. Our proprietary Bispecific Complement Engager (BiCE™) platform creates complement-powered immune engagers designed to selectively eliminate diseased cells. By recruiting C1q directly to malignant or pathological cells, BiCE™ antibodies activate complement precisely where it is needed, driving rapid and potent killing through a mechanism that does not rely on T cells. Building on three decades of complement research at Aarhus University, we spent years at Commit investigating how to design effective complement-powered immune engagers. That work produced the BiCE™ platform and, more recently, our first drug candidate, which is now heading to the clinic. We expect complement-powered immune engagers to become a new pillar of immunotherapy, alongside T cell engagers and cell therapies. Commit is backed by Bioqube Ventures, Novo Holdings, Korys and the BioInnovation Institute.

Commit Biologics Questions

Thomas Andresen is the CEO of Commit Biologics.

19 people are employed at Commit Biologics.

Top Commit Biologics Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users